Aduro has a broad pipeline and can rapidly develop new vaccines and new vaccine combinations. Shown below are our lead programs in oncology. We also have programs in infectious diseases, including malaria and HBV, and programs in biodefense, including tularemia.
Our lead program is the combination of CRS-207 and GVAX Pancreas in patients with pancreatic cancer. For more information, please see Clinical Trials.
Aduro is also evaluating CRS-207 in combination with chemotherapy in patients with mesothelioma. For more information, please see Clinical Trials.
ADU-214 is a bivalent Listeria-based vaccine that targets both mesothelin and an EGFR mutation known to be common in several diverse solid tumor malignancies.
Aduro is working with collaborators to design and fund a Phase 1 trial in ovarian cancer. In addition, Aduro is working with collaborators to
design and fund a Phase 1B trial to evaluate the combination of ADU-214
and radiation in patients with non-small-cell lung cancer.
Aduro collaborators are planning an investigator-sponsored Phase 1 clinical trial in patients with glioblastoma. The trial will use ADU-623, which is Aduro's first clinical bivalent Listeria-based vaccine.
Aduro has received a Congressionally Directed Medical Research Programs (CDMRP) grant from the Department of Defense to complete the preclinical development of a novel therapeutic cancer vaccine for prostate cancer. For more information, please read the press release.
CDNs are small molecules that signal through STING and induce a potent immune response. The first clinical indication has not yet been determined. For more information, please see cyclic dinucleotides.
STINGVAX is the combination of two of Aduro's platform technologies. For more information, please see GVAX and cyclic dinucleotides.